.png)
Bard PowerPort
TIVAD: Totally implanted vascular access device (TIVAD), (CVAD) central venous access device or port-a-cath
Blood clots Heart attacks Strokes Pulmonary embolisms Hemorrhages Sepsis Necrosi
- Do you or a loved one have an implanted TIVAD (Totally implanted vascular access device) or CVAD (central venous access device)?
- Do you suffer from complications or serious injuries?
What You Need to Know:
The FDA has received reports of hundreds of severe adverse incidents related to the implantable Bard PowerPort catheter. These incidents include device fractures and infections, which can potentially lead to life-threatening events. Your safety is paramount, and it's crucial to be aware of these risks associated with Bard PowerPort catheters.
Bard PowerPort devices utilize a material known as Chronoflex, a flexible polymer that incorporates barium. Elevated levels of barium can potentially instigate the degradation of the polymer, leading to problems like fractures, deterioration, fissures, and tubing cracks. When this happens, the defective port can fracture, migrate, and cause infections, which may result in serious injuries such as blood clots, heart attacks, strokes, pulmonary embolisms, hemorrhages, sepsis, or necrosis.
Despite numerous lawsuits, hundreds of serious adverse events reported, and the creation of new multidistrict litigation to address the claims of patients who have been harmed, Bard continues to market the device as safe and effective, and it remains approved by the FDA.
Bard PowerPort devices utilize a material known as Chronoflex, a flexible polymer that incorporates barium. Elevated levels of barium can potentially instigate the degradation of the polymer, leading to problems like fractures, deterioration, fissures, and tubing cracks. When this happens, the defective port can fracture, migrate, and cause infections, which may result in serious injuries such as blood clots, heart attacks, strokes, pulmonary embolisms, hemorrhages, sepsis, or necrosis.
Despite numerous lawsuits, hundreds of serious adverse events reported, and the creation of new multidistrict litigation to address the claims of patients who have been harmed, Bard continues to market the device as safe and effective, and it remains approved by the FDA.
